Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coherus Oncology (CHRS) Minority Interest (2016 - 2018)

Coherus Oncology (CHRS) has disclosed Minority Interest for 5 consecutive years, with -$1.3 million as the latest value for Q2 2018.

  • Quarterly Minority Interest fell 4.52% to -$1.3 million in Q2 2018 from the year-ago period, while the trailing twelve-month figure was -$1.3 million through Jun 2018, down 4.52% year-over-year, with the annual reading at -$1.3 million for FY2017, 9.89% down from the prior year.
  • Minority Interest hit -$1.3 million in Q2 2018 for Coherus Oncology, down from -$1.3 million in the prior quarter.
  • In the past five years, Minority Interest ranged from a high of -$44000.0 in Q4 2014 to a low of -$1.3 million in Q2 2018.
  • Historically, Minority Interest has averaged -$872250.0 across 5 years, with a median of -$1.1 million in 2016.
  • Biggest five-year swings in Minority Interest: crashed 1540.91% in 2015 and later dropped 4.52% in 2018.
  • Year by year, Minority Interest stood at -$44000.0 in 2014, then crashed by 1540.91% to -$722000.0 in 2015, then crashed by 62.47% to -$1.2 million in 2016, then decreased by 9.89% to -$1.3 million in 2017, then fell by 4.03% to -$1.3 million in 2018.
  • Business Quant data shows Minority Interest for CHRS at -$1.3 million in Q2 2018, -$1.3 million in Q1 2018, and -$1.3 million in Q4 2017.